-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Arsenic (ATO), also known as letter stone, red vitriol, white arsenic, etc.
This is an open label multi-center Phase II clinical trials, included in the period July 2013 to October 2015, 11 patients with active SLE from France 6 University Hospital, all patients immune fluorescent antinuclear antibody (ANA) are ≥1:80, SLE disease activity index (SLEDAI) score is still more than 6 points after receiving conventional hormone and immunosuppressive therapy
Safety assessments were conducted on all 11 patients.
At week 16, the median SLEDAI score dropped from 8 points at baseline to 3.
In 6 patients with positive anti-double-stranded DNA (dsDNA) antibodies at baseline, a downward trend in dsDNA levels was observed from the 4th week to the 8th week
In this clinical trial, a short course of intravenous injection of ATO showed encouraging efficacy and acceptable safety for SLE patients
Hamidou, M.
Arsenic (ATO), also known as letter stone, red vitriol, white arsenic, etc.
2 .
This is an open label multi-center Phase II clinical trials, included in the period July 2013 to October 2015, 11 patients with active SLE from France 6 University Hospital, all patients immune fluorescent antinuclear antibody (ANA) are ≥1:80, SLE disease activity index (SLEDAI) score is still more than 6 points after receiving conventional hormone and immunosuppressive therapy
immunity
11 people
At week 16, the median SLEDAI score dropped from 8 points at baseline to 3.
In 6 patients with positive anti-double-stranded DNA (dsDNA) antibodies at baseline, a downward trend in dsDNA levels was observed from the 4th week to the 8th week
In this clinical trial, a short course of intravenous injection of ATO showed encouraging efficacy and acceptable safety for SLE patients
Hamidou, M.
, Néel, A.
, Poupon, J.
et al.
Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).
Arthritis Res Ther 23, 70 ( 2021).
https://doi.
org/10.
1186/s13075-021-02454-6 .
org/10.
1186/s13075-021-02454-6
Leave a message here
